← Browse by Condition

Medical Condition

sickle cell disease

Total Trials

19

Recruiting Now

19

Trial Phases

Phase 2, Phase 1, Phase 2, Phase 4

ClinicalMetric tracks all active clinical trials for sickle cell disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — sickle cell disease Clinical Trials

How many clinical trials are currently recruiting for sickle cell disease?

ClinicalMetric currently tracks 19 actively recruiting clinical trials for sickle cell disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 19. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for sickle cell disease?

sickle cell disease research spans Phase 1 (2 trials), Phase 2 (7 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a sickle cell disease clinical trial?

Eligibility criteria for sickle cell disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

2

Phase 2

7

Phase 4

1

Top Sponsors

American Thrombosis and Hemostasis Network 2 trials

Novartis Pharmaceuticals 2 trials

University of Maryland, Baltimore 1 trial

University Hospitals Cleveland Medical Center 1 trial

University of Alabama at Birmingham 1 trial

Recruiting Clinical Trials

Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

University of Maryland, Baltim...

Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)

University Hospitals Cleveland...

NCT05336201 Phase 2

Cognitive Remediation Intervention to Prepare for Transition of Care

University of Alabama at Birmi...

ATHNdataset Registry

American Thrombosis and Hemost...

NCT07252050 Phase 1, Phase 2

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Arkansas Children's Hospital R...

Blood Sampling for Research Related to Sickle Cell Disease

National Institute of Diabetes...

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

American Thrombosis and Hemost...

NCT06872333 Phase 2

Allo HSCT for High Risk Hemoglobinopathies

Masonic Cancer Center, Univers...

Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

RTI International

NCT06546670 Phase 1, Phase 2

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

United States, Turke...

Novartis Pharmaceuticals

Cooperative Assessment of Late Effects for SCD Curative Therapies

Vanderbilt University Medical ...

Investigation of the Genetics of Hematologic Diseases

St. Jude Children's Research H...

Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)

Nemours Children's Clinic

NCT06578507 Phase 2

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

France, French Guian...

Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease

University of Pennsylvania

Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients

Centre Hospitalier Universitai...

NCT05953584 Phase 2

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke

India, Nigeria, Oman

Forma Therapeutics, Inc.

NCT04657822 Phase 4

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

United States, Belgi...

Novartis Pharmaceuticals

NCT03121001 Phase 2

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

University of Illinois at Chic...

Related Conditions

hemophilia (2) thrombosis (2) bleeding disorder (2) von willebrand diseases (2) graft failure (2) vaso occlusive pain episode in sickle cell disease (1) acute pain (1) cognitive impairment (1) adolescent behavior (1) self efficacy (1) health related behavior (1) coping skills (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology